Stock Quote

Cellect Biotechnology Reports Fourth Quarter and Full Year 2020 Financial and Operating Results

TEL AVIV, Israel, March 29, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: “APOP”), a developer of innovative technology that enables the functional selection of stem cells, today reported financial and operating results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.

On March 24, the Company announced a strategic merger agreement with privately held Quoin Pharmaceuticals, a U.S. based specialty pharmaceutical company focused on rare and orphan diseases. Under the terms of the merger agreement, Quoin has secured $25 million in committed funding from a highly regarded, institutional healthcare investor. Current Cellect shareholders will retain approximately 25% of the combined shares before investment. The merger is expected to close by the end of the second quarter of 2021. Cellect has also signed an agreement to sell its wholly-owned subsidiary company, Cellect Biotherapeutics, to EnCellX, Inc. - a newly founded biotechnology company based in San-Diego, CA. - to continue the development of Cellect’s products.

Recent Clinical Highlights

  • Due to the COVID-19 pandemic and the Company decision to shift attention and resources to the U.S. Phase I clinical trial, which is expected to enroll the first patient soon, the Company has elected to close the Phase 1/2 clinical trial being performed in Israel earlier than expected, since recruitment of the 12th and final patient was not assured in a timely manner.
  • To date, Data from the open label Israel Phase 1/2 clinical trial supports the Company’s optimism as it extends its clinical program to the U.S. The Company expects to publish the top line results of the Israel trial in Q2.

“Concurrent with our plans to seek strategic alternatives to maximize shareholder value, we also remained focus on advancing our clinical interests in the U.S.,” commented Dr. Shai Yarkoni, Chief Executive Officer. “We have signed a compelling business proposition with Quoin and a privately-held U.S. biotechnology company that allows our current shareholders to benefit from Quoin’s promising technology and the fruits of continued progress of our clinical programs as they reach critical inflections points through the issuance of contingent value rights to our shareholders in connection with the sale of Cellect Biotherapeutics.”

Fourth Quarter and Full Year 2020 Financial Results:

  • Research and development (R&D) expenses for the fourth quarter and for the full year of 2020 were $0.53 million and $1.83 million respectively, compared to $0.80 million in the fourth quarter of 2019 and $3.77 million for the full year of 2019. The decrease in R&D expenses for the full year of 2020 as compared to the full year of 2019 resulted from the reduction in our research and development activities, as we decreased the number of our employees engaged in research and related activities.
  • General and administrative (G&A) expenses for the fourth quarter and for the full year of 2020 were $0.67 million and $2.52 million respectively, compared to $0.74 million in the fourth quarter of 2019 and $3.18 million for the full year of 2019. The decrease in G&A expenses for the full year of 2020 as compared to the full year of 2019 resulted from the reduction in the company activities resulting from a decrease in the number of employees.
  • Finance expenses for the fourth quarter of 2020 were $0.38 million, and financial expenses were $1.27 million for the full year of 2020, compared to finance expenses of $0.35 million in the fourth quarter of 2019 and financial income of $1.72 million for the full year of 2019, respectively. The financial expenses in the full year of 2020 as compared to the financial income in the full year of 2019 is primarily due to the change in the fair value of the listed warrants granted in our U.S. initial public offering in 2016 and of the unregistered warrants granted in our registered direct offerings in 2019.
  • Total Comprehensive loss for the fourth quarter and for the full year of 2020 was $1.58 million and $5.62 million respectively, or $0.004 per share for the fourth quarter and $0.015 per share for the full year of 2020, respectively, compared to $1.89 million, or $0.008 per share, in the fourth quarter of 2019 and $5.23 million, or $0.025 per share, for the full year of 2019.

* For the convenience of the reader, the amounts above have been translated from NIS into U.S. dollars, at the representative rate of exchange on December 31, 2020 (U.S. $1 = NIS 3.215).

About Cellect Biotechnology Ltd.

Cellect Biotechnology (APOP) has developed a breakthrough technology for the selection of stem cells from any given tissue that aims to improve a variety of cell-based therapies.

The Company’s technology is expected to provide researchers, clinicians and pharmaceutical companies with the tools to rapidly isolate specific cells in quantity and quality, allowing cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The Company’s current clinical trial is aimed at bone marrow transplantations in cancer treatment.

Forward Looking Statements

This press release contains forward-looking statements about the Company’s expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Company’s history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company’s ability to continue as a going concern; or maintain its current operations; uncertainties involving any strategic transaction the Company may decide to enter into as the result of its current efforts to explore new strategic alternatives; uncertainties of cash flows and inability to meet working capital needs; the Company’s ability to obtain regulatory approvals; the Company’s ability to obtain favorable pre-clinical and clinical trial results; the Company’s technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Company’s clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Company’s ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Company’s industry; unforeseen scientific difficulties may develop with the Company’s technology; and the Company’s ability to retain or attract key employees whose knowledge is essential to the development of its products. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in Cellect Biotechnology Ltd.’s Annual Report on Form 20-F for the fiscal year ended December 31, 2020 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC’s website, www.sec.gov, and in the Company’s periodic filings with the SEC.

Contact
Cellect Biotechnology Ltd.
Eyal Leibovitz, Chief Financial Officer
www.cellect.co
+972-9-974-1444

Or

EVC Group LLC
Michael Polyviou
(732) 933-2754
mpolyviou@evcgroup.com


Cellect Biotechnology Ltd
Consolidated Statement of Operation

  Convenience             
  translation             
  Twelve months ended  Twelve months ended  Three months ended 
  December 31,  December 31,  December 31, 
  2020  2020  2019  2020  2019 
  Unaudited  Audited  Audited  Unaudited  Unaudited 
                
  U.S. dollars  NIS 
       
  (In thousands, except share and per share data) 
                
Research and development expenses  1,830   5,883   12,122   1,693   2,571 
                     
General and administrative expenses  2,523   8,111   10,210   2,167   2,378 
                     
Operating loss  4,353   13,994   22,332   3,860   4,949 
                     
Financial expenses (income) due to warrants exercisable into ADS  846   2,721   (7,022)  4   998 
                     
Other financial expenses (income), net  424   1,362   1,498   1,224   129 
                     
Total comprehensive loss  5,623   18,077   16,808   5,088   6,076 
                     
Loss per share:                    
                     
Basic and diluted loss per share  0.015   0.049   0.079   0.013   0.027 
                     
Weighted average number of shares outstanding used to compute basic and diluted loss per share  368,078,786   368,078,786   212,642,505   390,949,079   224,087,799 



Cellect Biotechnology Ltd
Consolidated Balance Sheet Data

  Convenience       
  translation       
  December 31,  December 31,  December 31, 
  2020  2020  2019 
  Unaudited  Audited  Audited 
          
  U.S. dollars  NIS 
       
ASSETS (In thousands, except share and per
share data)
 
CURRENT ASSETS:         
Cash and cash equivalents  5,277   16,964   18,106 
Other receivables  88   284   469 
             
   5,365   17,248   18,575 
NON-CURRENT ASSETS:            
Restricted cash  100   322   328 
Right of use - Assets under operating lease  219   705   1,035 
Other long-term assets  22   72   94 
Property, plant and equipment, net  384   1,232   1,288 
             
   725   2,331   2,745 
             
   6,090   19,579   21,320 
LIABILITIES AND
SHAREHOLDERS’ EQUITY
  
CURRENT LIABILITIES:            
Trade payables  121   389   158 
Leases liabilities  115   369   396 
Other payables  693   2,228   3,080 
   929   2,986   3,634 
NON-CURRENT LIABILITIES:            
Warrants to ADS  380   1,222   2,172 
Leases liabilities  122   391   677 
   502   1,613   2,849 
EQUITY:            
Ordinary shares of no par value:             
Authorized: 500,000,000 shares at December 31, 2019 and December 31 2020; Issued and outstanding: 224,087,799*) and 390,949,079*) shares as of December 31, 2019 and December 31, 2020, respectively.  -   -   - 
Additional Paid In Capital  39,452   126,838   108,598 
Share-based payments  5,135   16,508   16,528 
Treasury shares  (2,932)  (9,425)  (9,425)
Accumulated deficit  (36,996)  (118,941)  (100,864)
   4,659   14,980   14,837 
             
   6,090   19,579   21,320 


 *)Net of 2,641,693 treasury shares of the Company held by the Company.



Cellect Biotechnology Ltd
Consolidated Cash Flow Data

  Convenience             
  translation             
  Twelve months ended  Twelve months ended  Three months ended 
  December 31,  December 31,  December 31, 
  2020  2020  2019  2020  2019 
  Unaudited  Audited  Audited  Unaudited  Unaudited 
                
  U.S. dollars  NIS 
     (In thousands) 
Cash flows from operating activities:               
Total comprehensive loss  (5,623)  (18,077)  (16,808)  (5,088)  (6,076)
                     
Adjustments to reconcile net loss to net cash used in operating activities:                    
Exchange rate difference  (412)  (1,326)  1,036   (1,115)  (50)
Loss (gain) from revaluation of financial assets presented at fair value through profit and loss  -   -   -   -   (8)
Depreciation of Right of use - Assets under operating lease  115   369   433   97   (24)
Depreciation  109   350   373   94   88 
Finance expenses  27   88   128   40   128 
Issuance expenses  -   -   1,621   -   1,621 
Changes in fair value of traded and non traded warrants to ADS  847   2,722   (8,643)  4   708 
Share-based payment  229   738   2,708   262   807 
Decrease (increase) in other receivables  65   207   385   417   239 
Increase (decrease) in other payables  (193)  (621)  (1,663)  528   192 
Interest received  20   64   93   8   168 
Net cash used in operating activities  (4,816)  (15,486)  (20,337)  (4,753)  (2,207)
                     
Cash flows from investing activities:                    
Restricted deposit, net  2   6   9   7   9 
Proceeds received from the sale of fixed assets  11   35   6   -   6 
(Purchase) Sales of marketable securities measured at fair value through profit and loss  -   -   -   -   - 
Purchase of property, plant and equipment  (103)  (329)  (123)  (170)  (3)
Net cash provided by investing activities  (90)  (288)  (108)  (163)  12 
Cash flows from financing activities:                    
Exercise of warrants and stock options into shares  1,435   4,615   -   -   - 
Repayment on account of lease liabilities  (137)  (441)  (522)  (117)  (101)
Issue of share capital and warrants, net of issue costs  2,860   9,194   22,393   -   (1,330)
Net cash provided (used) by financing activities  4,158   13,368   21,871   (117)  (1,431)
Exchange differences on balances of cash and cash equivalents  393   1,264   (1,129)  1,108   (117)
Increase (decrease) in cash and cash equivalents  (355)  (1,142)  297   (3,925)  (3,743)
Balance of cash and cash equivalents at the beginning of the period  5,632   18,106   17,809   20,889   21,849 
Balance of cash and cash equivalents at the end of the period  5,277   16,964   18,106   16,964   18,106 


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.